Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity
暂无分享,去创建一个
C. Wegner | W. Brück | C. Stadelmann | S. Nessler | M. Schön | M. Schön | Martina Ott | M. Harden | G. Bernhardt | J. Strauss | E. Avendaño-Guzmán | E. Ullrich | Carolin Dreyer | M. P. Schön
[1] T. Leanderson,et al. Paquinimod prevents development of diabetes in the non-obese diabetic (NOD) mouse , 2018, PloS one.
[2] C. Wegner,et al. Differential contribution of immune effector mechanisms to cortical demyelination in multiple sclerosis , 2017, Acta Neuropathologica.
[3] Qinghua Jiang,et al. Genetic variant rs763361 regulates multiple sclerosis CD226 gene expression , 2017, Proceedings of the National Academy of Sciences.
[4] Ignacio S. Caballero,et al. Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor , 2016, Proceedings of the National Academy of Sciences.
[5] T. Leanderson,et al. Erratum to: The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b+ Ly6Chi cells to tumor tissue reduces tumor growth , 2016, BMC Cancer.
[6] R. Hohlfeld,et al. Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation , 2016, Proceedings of the National Academy of Sciences.
[7] T. Leanderson,et al. The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b+ Ly6Chi cells to tumor tissue reduces tumor growth , 2016, BMC Cancer.
[8] T. Leanderson,et al. Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment , 2015, Journal of Immunotherapy for Cancer.
[9] R. Germain,et al. NK-DC crosstalk controls the autopathogenic Th 17 response through an innate IFN-– IL-27 axis , 2015 .
[10] Z. Qiu,et al. CD226 gene polymorphisms are associated with non-small-cell lung cancer in the Chinese Han population , 2015, Therapeutics and clinical risk management.
[11] F. Souza-Fonseca-Guimaraes,et al. DNAM-1 expression marks an alternative program of NK cell maturation. , 2015, Cell reports.
[12] M. Smyth,et al. Balancing natural killer cell activation through paired receptors , 2015, Nature Reviews Immunology.
[13] L. Ellis,et al. Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models , 2014, Cancer Immunology Research.
[14] L. Lanier,et al. Costimulatory molecule DNAM-1 is essential for optimal differentiation of memory natural killer cells during mouse cytomegalovirus infection. , 2014, Immunity.
[15] M. Mcgrath,et al. Cutting Edge: DNAX Accessory Molecule 1–Deficient CD8+ T Cells Display Immunological Synapse Defects That Impair Antitumor Immunity , 2014, The Journal of Immunology.
[16] P. Basse,et al. NK cells in the tumor microenvironment. , 2014, Critical reviews in oncogenesis.
[17] H. Kohrt,et al. Modulation of natural killer cell antitumor activity by the aryl hydrocarbon receptor , 2013, Proceedings of the National Academy of Sciences.
[18] T. Leanderson,et al. Amelioration of experimental autoimmune encephalomyelitis by the quinoline-3-carboxamide paquinimod: reduced priming of proinflammatory effector CD4(+) T cells. , 2013, The American journal of pathology.
[19] F. Zipp,et al. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. , 2013, Brain : a journal of neurology.
[20] F. Paul,et al. Characterization of natural killer cells in paired CSF and blood samples during neuroinflammation , 2013, Journal of Neuroimmunology.
[21] E. Ullrich,et al. The interaction of NK cells and dendritic cells in the tumor environment: how to enforce NK cell & DC action under immunosuppressive conditions? , 2012, Current medicinal chemistry.
[22] R. Sobel,et al. Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity , 2012, PloS one.
[23] T. Waldmann,et al. Intrathecal effects of daclizumab treatment of multiple sclerosis , 2011, Neurology.
[24] D. Maric,et al. Unexpected Role for Granzyme K in CD56bright NK Cell-Mediated Immunoregulation of Multiple Sclerosis , 2011, The Journal of Immunology.
[25] Javier Martín,et al. A 3'-untranslated region variant is associated with impaired expression of CD226 in T and natural killer T cells and is associated with susceptibility to systemic lupus erythematosus. , 2010, Arthritis and rheumatism.
[26] H. Ljunggren,et al. Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome , 2010, Leukemia.
[27] F. Shi,et al. Central nervous system (CNS)–resident natural killer cells suppress Th17 responses and CNS autoimmune pathology , 2010, The Journal of experimental medicine.
[28] G. Weiner,et al. Rituximab: mechanism of action. , 2010, Seminars in hematology.
[29] Johan Vallon-Christersson,et al. Open Access Research , 2022 .
[30] M. Colonna,et al. DNAM-1/CD155 Interactions Promote Cytokine and NK Cell-Mediated Suppression of Poorly Immunogenic Melanoma Metastases , 2009, The Journal of Immunology.
[31] H. Ljunggren,et al. Down-regulating Dnam-1 on Nk Cells Cd155 Impair Tumor Targeting by Primary Human Tumor Cells Expressing , 2022 .
[32] A. Chan,et al. Novel association of the CD226 (DNAM-1) Gly307Ser polymorphism in Wegener's granulomatosis and confirmation for multiple sclerosis in German patients , 2009, Genes and Immunity.
[33] E. Kremmer,et al. Heterogeneous expression of the adhesion receptor CD226 on murine NK and T cells and its function in NK‐mediated killing of immature dendritic cells , 2009, Journal of leukocyte biology.
[34] J. Lünemann,et al. Regulatory NK-Cell Functions in Inflammation and Autoimmunity , 2009, Molecular medicine.
[35] D. Schadendorf,et al. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. , 2009, The Journal of clinical investigation.
[36] M. Colonna,et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors , 2008, The Journal of experimental medicine.
[37] Eric Vivier,et al. Functions of natural killer cells , 2008, Nature Immunology.
[38] A. Flügel,et al. A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats. , 2008, The Journal of clinical investigation.
[39] H. Young,et al. In Vivo Regulation of Experimental Autoimmune Encephalomyelitis by NK Cells: Alteration of Primary Adaptive Responses12 , 2008, The Journal of Immunology.
[40] Bernhard Hemmer,et al. Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage. , 2007, Brain : a journal of neurology.
[41] K. Wucherpfennig,et al. Regulation of activated CD4+ T cells by NK cells via the Qa-1-NKG2A inhibitory pathway. , 2007, Immunity.
[42] V. Kuchroo,et al. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. , 2006, The Journal of clinical investigation.
[43] Steffen Jung,et al. The FASEB Journal • Research Communication The neuronal chemokine CX3CL1/fractalkine , 2022 .
[44] T. Waldmann,et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[45] M. Smyth,et al. CD27 Dissects Mature NK Cells into Two Subsets with Distinct Responsiveness and Migratory Capacity1 , 2006, The Journal of Immunology.
[46] T. Tabira,et al. Mechanism of natural killer (NK) cell regulatory role in experimental autoimmune encephalomyelitis , 2005, Journal of Neuroimmunology.
[47] T. Yamamura,et al. The regulatory role of natural killer cells in multiple sclerosis. , 2004, Brain : a journal of neurology.
[48] D. Paty,et al. Clinical relapses of multiple sclerosis are associated with ‘novel’ valleys in natural killer cell functional activity , 2003, Journal of Neuroimmunology.
[49] L. Moretta,et al. Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule , 2003, The Journal of experimental medicine.
[50] Steffen Jung,et al. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. , 2002, Immunity.
[51] R. Smeltz,et al. Inhibition of autoimmune T cell responses in the DA rat by bone marrow-derived NK cells in vitro: implications for autoimmunity. , 1999, Journal of immunology.
[52] H. Lassmann,et al. B Lymphocytes Producing Demyelinating Autoantibodies: Development and Function in Gene-targeted Transgenic Mice , 1998, Journal of Neuroimmunology.
[53] K. Kohyama,et al. Role of natural killer cells and TCRγ δ T cells in acute autoimmune encephalomyelitis , 1998 .
[54] T. Tabira,et al. Regulation of Experimental Autoimmune Encephalomyelitis by Natural Killer (NK) Cells , 1997, The Journal of experimental medicine.
[55] Y. Suzuki,et al. Role of natural killer cells and TCR gamma delta T cells in acute autoimmune encephalomyelitis. , 1998, European journal of immunology.
[56] T. Mcclanahan,et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. , 1996, Immunity.
[57] Susumu Tonegawa,et al. RAG-1-deficient mice have no mature B and T lymphocytes , 1992, Cell.
[58] I. Fidler. Biological behavior of malignant melanoma cells correlated to their survival in vivo. , 1975, Cancer research.
[59] David Gottlieb,et al. Mechanism of Action , 2012, Antibiotics.